|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bast RC, Feeney M, Lazarus H, Nadler LM,
Colvin RB and Knapp RC: Reactivity of a monoclonal antibody with
human ovarian carcinoma. J Clin Invest. 68:1331–1337. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sevinc A, Adli M, Kalender ME and Camci C:
Benign causes of increased serum CA-125 concentration. Lancet
Oncol. 8:1054–1055. 2019. View Article : Google Scholar
|
|
4
|
Medeiros LR, Rosa DD, da Rosa MI and
Bozzetti MC: Accuracy of CA 125 in the diagnosis of ovarian tumors:
A quantitative systematic review. Eur J Obstet Gynecol Reprod Biol.
142:99–105. 2019. View Article : Google Scholar
|
|
5
|
Engelen MJ, de Bruijn HW, Hollema H, ten
Hoor KA, Willemse PH, Aalders JG and van der Zee AG: Serum CA 125,
carcinoembryonic antigen, and CA 19-9 as tumor markers in
borderline ovarian tumors. Gynecol Oncol. 78:16–20. 2019.
View Article : Google Scholar
|
|
6
|
Simmons AR, Baggerly K and Bast RC: The
emerging role of HE4 in the evaluation of epithelial ovarian and
endometrial carcinomas. Oncology (Williston Park). 27:548–556.
2019.
|
|
7
|
Lu R, Sun X, Xiao R, Zhou L, Gao X and Guo
L: Human epididymis protein 4 (HE4) plays a key role in ovarian
cancer cell adhesion and motility. Biochem Biophys Res Commun.
419:274–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schummer M, Ng WV, Bumgarner RE, Nelson
PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY and
Hood L: Comparative hybridization of an array of 21,500 ovarian
cDNAs for the discovery of genes overexpressed in ovarian
carcinomas. Gene. 238:375–385. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Granato T, Porpora MG, Longo F, Angeloni
A, Manganaro L and Anastasi E: HE4 in the differential diagnosis of
ovarian masses. Clin Chim Acta. 446:147–155. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hallamaa M, Suvitie P, Huhtinen K,
Matomäki J, Poutanen M and Perheentupa A: Serum HE4 concentration
is not dependent on menstrual cycle or hormonal treatment among
endometriosis patients and healthy premenopausal women. Gynecol
Oncol. 125:667–672. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moore RG, Miller MC, Eklund EE, Lu H, Bast
RC and Lambert-Messerlian G: Serum levels of the ovarian cancer
biomarker HE4 are decreased in pregnancy and increase with age. Am
J Obstet Gynecol. 206:349.e1–349.e7. 2012. View Article : Google Scholar
|
|
12
|
Moore RG, McMeekin DS, Brown AK,
DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC
Jr and Skates SJ: A novel multiple marker bioassay utilizing HE4
and CA125 for the prediction of ovarian cancer in patients with a
pelvic mass. Gynecol Oncol. 112:40–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moore RG, Miller MC, Disilvestro P,
Landrum LM, Gajewski W, Ball JJ and Skates SJ: Evaluation of the
diagnostic accuracy of the risk of ovarian malignancy algorithm in
women with a pelvic mass. Obstet Gynecol. 118:280–288. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Drapkin R, von Horsten HH, Lin Y, Mok SC,
Crum CP, Welch WR and Hecht JL: Human epididymis protein 4 (HE4) is
a secreted glycoprotein that is overexpressed by serous and
endometrioid ovarian carcinomas. Cancer Res. 65:2162–2169. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim B, Park Y, Kim B, Ahn HJ, Lee KA,
Chung JE and Han SW: Diagnostic performance of CA 125, HE4, and
risk of Ovarian Malignancy Algorithm for ovarian cancer. J Clin Lab
Anal. 33:e226242019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Molina R, Escudero JM, Augé JM, Filella X,
Foj L, Torné A, Lejarcegui J and Pahisa J: HE4 a novel tumour
marker for ovarian cancer: Comparison with CA 125 and ROMA
algorithm in patients with gynaecological diseases. Tumor Biol.
32:1087–1095. 2011. View Article : Google Scholar
|
|
17
|
Romeo V, Framarino Dei Malatesta M, Nudo
F, Simonelli L, Derme M and Berloco PB: Is HE4 serum level a valid
screening test in women candidates for kidney transplant? A case
report and a review of literature. Clin Ter. 165:e162–e165.
2014.PubMed/NCBI
|
|
18
|
Anton C, Carvalho FM, Oliveira EI, Maciel
GAR, Baracat EC and Carvalho JP: A comparison of CA125, HE4, risk
ovarian malignancy algorithm (ROMA), and risk malignancy index
(RMI) for the classification of ovarian masses. Clinics (Sao
Paulo). 67:437–441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mutch DG and Prat J: 2014 FIGO staging for
ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol.
133:401–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ruggeri G, Bandiera E, Zanotti L, Belloli
S, Ravaggi A, Romani C, Bignotti E, Tassi RA, Tognon G, Galli C, et
al: HE4 and epithelial ovarian cancer: Comparison and clinical
evaluation of two immunoassays and a combination algorithm. Clin
Chim Acta. 412:1447–1453. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lenhard M, Stieber P, Hertlein L,
Kirschenhofer A, Fürst S, Mayr D, Nagel D, Hofmann K, Krocker K and
Burges A: The diagnostic accuracy of two human epididymis protein 4
(HE4) testing systems in combination with CA125 in the differential
diagnosis of ovarian masses. Clin Chem Lab Med. 49:2081–2088. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chan KK, Chen CA, Nam JH, Ochiai K,
Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA
and Sumpaico WW: The use of HE4 in the prediction of ovarian cancer
in Asian women with a pelvic mass. Gynecol Oncol. 128:239–244.
2019. View Article : Google Scholar
|
|
23
|
Karlsen MA, Høgdall EV, Christensen IJ,
Borgfeldt C, Kalapotharakos G, Zdrazilova-Dubska L, Chovanec J, Lok
CA, Stiekema A, Mutz-Dehbalaie I, et al: A novel diagnostic index
combining HE4, CA125 and age may improve triage of women with
suspected ovarian cancer-An international multicenter study in
women with an ovarian mass. Gynecol Oncol. 138:640–646. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dayyani F, Uhlig S, Colson B, Simon K,
Rolny V, Morgenstern D and Schlumbrecht M: Diagnostic performance
of risk of ovarian malignancy algorithm against CA125 and HE4 in
connection with ovarian cancer: A Meta-analysis. Int J Gynecol
Cancer. 26:1586–1593. 2019. View Article : Google Scholar
|
|
25
|
Wolman I: Berek and Novak's Gynecology
15th Edition. J Obstet Gynecol India. 2014.
|
